[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Atom Therapeutics Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":124},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,67,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100617782","phase-2-evaluate-the-efficacy-and-safety-of-abp-671-in-subjects-with-chronic-kidney-disease-and-hyperuricaemia-100617782",false,"NCT07323095","Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia","A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia","Inclusion Criteria:\n\n* Male or female aged 18-75 years , who voluntarily participate in this clinical trial, understand and comply with the procedures stipulated in this study\n* Patients who have been diagnosed with CKD based on Clinical Practice Guideline\n* During screening, body mass index (BMI) was ≥18.0 and ≤ 40.0 kg\u002Fm2\n* The sUA levels \\> 420 μmol\u002FL (7.0 mg\u002FdL)\n\nExclusion Criteria:\n\n* History of renal transplantation\n* The 24-hour urinary protein ≥ 3.5 g\u002Fday\n* Liver function abnormality: aspartate aminotransferase or alanine aminotransferase, or alkaline phosphatase \\> 3 times the upper limit of normal value (ULN)\n* Subjects with mental disorders who are unable to communicate normally with the investigator\n* Subjects who have participated in another clinical study during the screening period are within 30 days of the last dose of the study drug in another study\n* The investigator judged that the subject was not suitable for participation in this study","ALL","18 Years","75 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40",[27],"Chronic Kidney Disease","NOT_YET_RECRUITING","2026-06-03",{"date":31,"type":32},"2026-06-04","ACTUAL",{"date":34,"type":21},"2026-06-30",{"date":36,"type":21},"2028-01-31",{"name":38,"class":39},"Atom Therapeutics Co., Ltd","INDUSTRY",10,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100616297","phase-2-efficacy-safety-and-poppk-profile-of-abp-745-in-patients-with-atherosclerosis-100616297","NCT07303777","Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics (PopPK) Profile of ABP-745 in Patients With Atherosclerosis","Inclusion Criteria:\n\nUnless otherwise specified, subjects must meet all of the following criteria at screening:\n\n* Diagnosed with coronary at herosclerosis, and coronary angiography.\n* Male or female at 18-75 years of age (inclusive).\n* Weight ≥40 kg.\n* Currently using any oral lipid-lowering therapy.\n* Able to understand and willing to sign an ICF and comply with study requirements.\n* A woman or man of childbearing potential agreeing to use medically approved contraceptive methods from the screening until 3 months after the last study dose.\n\nExclusion Criteria:\n\nUnless otherwise specified, subjects are excluded from the study if any of the following criteria is met:\n\n* History of stroke within the past 6 months.\n* Uncontrolled arrhythmia within 3 months prior to screening.\n* Evidence of any active or suspected cancer within 3 years prior to the screening.\n* Having undergone any major surgery within 3 months prior to the screening or planning to undergo any major surgery during the study.\n* Presence or suspicion of ongoing of any serious infection.\n* Human immunodeficiency virus (HIV) infection.",{"count":49,"type":21},200,[24],"This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.",[53,54,55],"Atherosclerosis Cardiovascular Disease","ASCVD","ASCVD Management",[54,57],"ABP-745","RECRUITING","2026-04-23",{"date":61,"type":32},"2026-04-28",{"date":59,"type":32},{"date":64,"type":21},"2028-04",{"name":38,"class":39},33,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100621234","phase-1-drug-drug-interaction-study-of-abp-671-in-gout-patients-100621234","NCT07367971","Drug-Drug Interaction Study of ABP-671 in Gout Patients","Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients","Inclusion Criteria:\n\n* Adults 18-75 years with clinical diagnosis of gout.\n* Stable Allopurinol therapy QD for ≥14 days prior to Day 1.\n* Cohort N: Normal renal function.\n* Cohort R: Moderate renal impairment.\n\nExclusion Criteria:\n\n* Clinically significant hepatic impairment.\n* History of Allopurinol hypersensitivity.\n* Pregnancy or breastfeeding.",{"count":75,"type":21},20,[77],"PHASE1","This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.",[80,81,82],"Gout Chronic","Gout","DDI (Drug-Drug Interaction)",[84,80,85],"gout","ABP-671","2026-04-12",{"date":88,"type":32},"2026-04-14",{"date":90,"type":32},"2026-01-23",{"date":92,"type":21},"2026-08-31",{"name":38,"class":39},1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100604108","phase-2-safety-and-efficacy-of-abp-745-in-participants-with-an-acute-gout-flare-100604108","NCT07145229","Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare","A Randomized, Double-blind, Multicenter, Colchicine and Placebo-controlled Study to Evaluate the Efficacy and Safety of ABP-745 in Subjects With an Acute Gout Flare","Key Inclusion Criteria:\n\nSubjects are eligible for the study if they meet all of the following Inclusion Criteria:\n\n* Age 18-70 years old (inclusive), male or female.\n* Body mass index (BMI)18-40 kg\u002Fm2 (inclusive).\n* Medical history and current findings consistent with diagnosis of gouty arthritis.\n* Subjects must have experienced 2 or more gout flares within 12 months prior to screening.\n* Onset of an acute gout flare, within 6 months\n* Patients receiving ULT agents (such as allopurinol, febuxostat, probenecid, etc.) must be on stable doses of these drugs prior to first dose of study drug (and remain on the same dose throughout the Treatment Period).\n* Subjects agree to maintain a stable lifestyle (such as diet and exercise) during the study period.\n\nKey Exclusion Criteria:\n\nSubjects are excluded from the study if one or more of the following criteria are met:\n\n* Administration of oral prednisone ≥ 10 mg or equivalent doses of other glucocorticoids, or use of narcotics, within 24 hours prior to first dose of study drug, or intramuscular, intravenous, or intra-articular injection of any glucocorticoid within 14 days prior to first dose of study drug.\n* Use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) prior to first dose dose of study drug, at the investigator's discretion.\n* Administration of colchicine or ABP-745 within 14 days prior to first dose of study drug.\n* Subjects took any investigational drug in any clinical study within 1 month prior to first dose of study drug and throughout the study period.\n* Administration of pegloticase, or methotrexate, or any biologic IL-1 blocker, TNF inhibitor, or other biological agent within 30 days prior to first dose of study drug or within 5 half-lives of the study drug prior to the first dose of study drug, whichever is longer.\n* Administration of muscle relaxants, central stimulants, barbiturates, etc. within 30 days prior to first dose of study drug or within 5 half-lives of the drug prior to the first dose of study drug, whichever is longer.\n* Secondary gout (e.g., gout induced by chemotherapy, transplant-related gout).\n* Subjects with a current diagnosis or history of rheumatoid arthritis, psoriatic arthritis, evidence or suspicion of infectious\u002Fseptic arthritis, calcium pyrophosphate (CPP) crystal arthritis, acute polyarticular gout (4 or more joints), multiple sclerosis or any other demyelinating disease, or; major chronic inflammatory disease or connective tissue disease other than RA or psoriatic arthritis (PsA), including but not limited to fibromyalgia or systemic lupus erythematosus (with the exception of secondary Sjögrens syndrome, etc.); with arthritis due to any cause other than gout that may confound any study assessments per Investigator discretion or Prosthetic joint infection within 5 years of screening, or native joint infection within 1 year of screening\n* Current anticoagulation therapy, thrombocytopenia, or diseases with a risk of thrombocytopenia, such as aplastic anemia, hypersplenism, or known hemorrhagic diseases like idiopathic thrombocytopenic purpura or hemophilia.\n* History of malignancy within 5 years prior to screening, excluding localized cancers such as basal cell carcinoma.\n* Presence of significant diseases, including but not limited to: uncontrolled hypertension (systolic blood pressure ≥160 or diastolic blood pressure ≥100 mmHg), congestive heart failure (New York Heart Association \\[NYHA\\] class III or above), uncontrolled type 1 or 2 diabetes mellitus (hemoglobin A1c \\[HbA1c\\] \\>8.5%). Inclusion will be determined by the Investigator based on the subject's specific condition.\n* Women of childbearing potential as defined by Appendix 2.\n* Experienced only no or mild gout-related pain prior to first dose of study drug.\n* Use of gout flare prophylaxis (e.g., colchicine, NSAIDs, prednisone\u002Fmethylprednisolone) at the time of randomization based on conversation with subject and self-reported.\n* Corona Virus Disease (COVID) vaccination in the 4 weeks prior to randomization.","70 Years",{"count":104,"type":21},380,[24],"A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.",[108,109,110,111],"Acute Gouty Arthritis","Gout Flare","Gout Flares","Acute Gout Flare",[81,109,113,114,57],"Colchicine","Acute gout flare","2025-12-04",{"date":117,"type":32},"2025-12-08",{"date":119,"type":32},"2025-08-26",{"date":121,"type":21},"2026-06",{"name":38,"class":39},38,""]